You have read all your free articles, to continue reading subscribe to read the rest of this content.
Medivir communicates an update on the status of the development of JNJ-4178, the triple combination of simeprevir, odalasvir and AL-335, following The International Liver Congress 2017 of the European Association for the Study of the Liver (EASL), which was held in Amsterdam, on 19-23 April. DataAlready a subscriber Login You…
BioInvent International has received verbal notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold (i.e. no further dosing of patients) has been placed on BioInvent’s current clinical Phase II study with the antibody BI-505 in patients with multiple myeloma. BioInventAlready a subscriber Login You have…
Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has giveAlready a subscriber Login You…
Affibody has announced the completion of the ABY-039 Phase 1 trial, and the termination of the ABY-039 program due to tolerability observations that would limit the target product profile of subcutaneous high dose once monthly maintentance injections. Based on these observations Alexion has termiAlready a subscriber Login You have read…
